MET, a transmembrane tyrosine kinase receptor, is central to the processes of cancer cell migration, invasion, proliferation, and metastasis.[36] MET amplification and/or mutations are found in many human malignancies, including NSCLC, and predicts both resistane to EGFR TKIs and poor survival.[36–38] Thus, EGFR and MET may cooperate in driving tumorigenesis. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.